Collectively our data demonstrates that combined inhibition of Mcl-1 and AKT/PI3Kβ is effective at killing breast cancer cells resistant to PI3Ki and AKTi in which resistance is caused by sustained mTORC1 signaling. The gene discussed is AKT1; the disease is breast carcinoma.